ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1365	National Cancer Institute	Html	en	Treatment-Related Nausea and Vomiting (PDQ®)–Health Professional Version	Expert-reviewed information summary about nausea and vomiting as complications of cancer or its treatment. Approaches to the management of nausea and vomiting are discussed.	Navari RM 0.607101 emetogenic cancer chemotherapy 0.63983 Eur J Cancer 0.609061 delayed chemotherapy-induced nausea 0.625115 prevention 0.607994 vomiting 0.735606 moderately emetogenic cancer 0.588642 Hesketh PJ 0.626918 chemotherapy-induced nausea 0.995758 patients 0.657649 postchemotherapy nausea 0.593584 Ann Oncol 0.583271 future chemotherapy cycles 0.584523 cancer chemotherapy 0.674463 postchemotherapy nausea interrelate 0.583875 Cancer Treat Rep 0.590867 receptor antagonist 0.645678 et al. 0.731812 multiday chemotherapy regimen. 0.581142 study 0.614153 3-day chemotherapy regimens 0.58215 emetogenic chemotherapy-induced nausea 0.655987 high-dose cisplatin chemotherapy 0.594488 highly emetogenic chemotherapy 0.717945	cisplatin chemotherapy 0.641758 delayed cisplatin-induced nausea 0.593234 PUBMED Abstract 0.729569 moderately emetogenic chemotherapy 0.836636 Support Care Cancer 0.895503 emetogenic cisplatin-based chemotherapy 0.601411 emetogenic multi-day chemotherapy 0.600149 Patients Receiving Chemotherapy 0.603022 lung cancer chemotherapy 0.587479 multiday chemotherapy 0.602924 dexamethasone 0.645924 Abstract 0.798738 cisplatin-induced emesis 0.607512 Clin Oncol 0.771609 multiday chemotherapy regimen 0.588792 chemotherapy regimen 0.594004 multiple-day cisplatin chemotherapy 0.590292 antiemetic therapy 0.590387 emetogenic multiple-day chemotherapy 0.598957 antiemetic efficacy 0.593069 acute chemotherapy-induced nausea 0.663254 breakthrough chemotherapy-induced nausea 0.630049 acute nausea 0.588031 cisplatin combination chemotherapy 0.606904	CLICK HERE
1471	National Cancer Institute	Html	en	Small Intestine Cancer Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of small intestine cancer.	illustrations 0.418999 duodenum. 0.42103 PDQ cancer information 0.903829 resectable leiomyosarcoma 0.536755 PDQ information 0.645092 Small intestine carcinomas 0.711426 multiple sites 0.521204 scientific images 0.511301 malignant lesions 0.542214 text 0.419438 cancer information summary 0.765692 National Institutes 0.515005 sentence 0.423056 breast cancer prevention 0.606867 author 0.434223 NCI’s PDQ 0.679179 PDQ Adult Treatment 0.75546 adenocarcinomas 0.421075 NCI PDQ cancer 0.783554 carcinoid tumors 0.53815 small intestine 0.82655 jejunum 0.420595 ileum 0.420633 relates 0.424246 resectable adenocarcinoma 0.544916	5-year survival rate 0.903147 common primary sarcoma 0.632045 content 0.419494 predominant modality 0.550555 literature 0.41999 overall 5-year survival 0.674093 National Cancer Institute 0.792644 trademark 0.418975 Editorial Board 0.520308 ability 0.4195 PDQ documents 0.647487 primary malignant tumors 0.647543 owner 0.419281 Visuals Online 0.515575 entirety 0.426542 Health 0.419895 cancer-related images 0.526463 permission 0.44717 NIH 0.422847 gastrointestinal malignancies 0.551608 resection 0.436749 duodenum 0.432045 policy statement 0.518223 independent review 0.515819	CLICK HERE
1567	National Cancer Institute	Html	en	Metastatic Squamous Neck Cancer with Occult Primary Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of metastatic squamous neck cancer with occult primary.	cancer treatment 0.331255 neck muscles 0.258524 cancer spreads 0.287607 metastatic cancer 0.293108 malignant tumor cells 0.281382 body 0.321816 PDQ cancer information 0.347021 squamous cells 0.294186 clinical trial search 0.272504 external radiation treatment 0.262886 clinical trials 0.659393 cancer information summary 0.31748 clinical trial 0.463543 squamous cell cancer 0.363064 breast cancer prevention 0.264993 radical neck dissection 0.322726 patients 0.300058 earlier clinical trials 0.261657 treatment clinical trial 0.277097 PDQ Adult Treatment 0.268031 different types 0.294996 NCI PDQ cancer 0.286254 tests 0.272201 radiation therapy 0.490196 Treatment Editorial Board 0.283384	lung cancer cells 0.288937 currently used treatment 0.262475 metastatic squamous neck 0.988686 treatment 0.481959 Occult Primary Treatment 0.275159 new cancer treatments 0.27464 cancer cells 0.387801 Cancer Information Service 0.273937 PDQ Metastatic Squamous 0.312989 Hyperfractionated radiation therapy 0.272771 treatment clinical trials 0.300592 squamous neck cancer 0.954253 National Cancer Institute 0.34026 occult primary 0.527765 new treatment 0.321855 new treatments 0.258619 Cancer Care page 0.264657 primary tumor 0.396235 cancer research process 0.267043 cancer clinical trials 0.302055 treatment options 0.305059 cancer information summaries 0.272694 comprehensive cancer information 0.272807 occult primary tumor 0.271623	CLICK HERE
1642	National Cancer Institute	Html	en	714-X (PDQ®)–Patient Version	714-X is made by mixing chemicals with camphor, a natural substance that comes from the wood and bark of the camphor tree. Read about the theory behind using 714-X and its current use in cancer patients.	peer-reviewed scientific journals 0.537641 treatment 0.534968 cancer treatment 0.501509 cancer prevention 0.385702 Information Service 1-800-4-CANCER 0.351897 Complementary Therapies Editorial 0.514523 United States 0.392202 Cancer Information Specialist 0.412867 Drug Administration 0.382831 NCI Best Case 0.355021 Cancer Information Service 0.561203 PDQ cancer information 0.744788 Cancer Complementary 0.449411 CAM therapies 0.422313 treatment clinical trials 0.37249 National Cancer Institute 0.876336 clinical trials 0.717035 alternative medicine 0.550954 health care 0.367057 scientific journals 0.644656 cancer information summary 0.608674 alternative cancer therapies 0.435258 Federal Trade Commission 0.400026 National Institutes 0.384082	clinical trial 0.420566 National Center 0.380596 CAM cancer research 0.409541 new treatment 0.361031 breast cancer prevention 0.380639 PDQ 714-X 0.397489 PDQ summaries 0.352729 cancer patients 0.471011 Cancer Care page 0.383195 latest published information 0.365664 NCI’s PDQ 0.390788 PDQ summary 0.383221 Integrative Health 0.378723 NCI PDQ cancer 0.513504 cancer information database 0.431786 alternative therapies 0.488998 cancer information summaries 0.432385 Therapies Editorial Board 0.457631 cancer 0.995087 research studies 0.395284 714-X 0.480793 fight cancer cells 0.39917 PDQ Integrative 0.349747	CLICK HERE
1662	National Cancer Institute	Html	en	Childhood Craniopharyngioma Treatment (PDQ®)–Patient Version	Childhood craniopharyngiomas are benign (not cancer) brain tumors found near the pituitary gland. Learn about the signs, tests to diagnose, and treatment (surgery, radiation therapy, chemotherapy, and immunotherapy) of pediatric craniopharyngioma in this expert-reviewed summary.	cancer treatment 0.48468 biologic therapy 0.507196 metastatic brain tumors 0.486695 ongoing clinical trials 0.484802 type 0.50142 PDQ cancer information 0.574719 clinical trial search 0.540589 brain tumors 0.522888 clinical trials 0.951944 Tumors Treatment Overview 0.504097 Pediatric Treatment Editorial 0.495313 cancer information summary 0.533129 External-beam radiation therapy 0.488413 clinical trial 0.688299 treatment clinical trial 0.507181 NCI PDQ cancer 0.492501 radiation therapy 0.972274 Treatment Editorial Board 0.499227 3-dimensional radiation therapy 0.515967 late effects 0.510845 currently used treatment 0.491406 treatment 0.796928 PDQ treatment summary 0.532401 pituitary gland 0.574023 primary brain tumors 0.487104	PDQ Pediatric Treatment 0.494857 childhood craniopharyngioma 0.61051 Benign brain tumors 0.485617 treatment clinical trials 0.53534 National Cancer Institute 0.529019 tumor cells 0.70293 spinal cord 0.496884 tumor treatment 0.551247 optic nerves 0.511248 Childhood Craniopharyngioma Treatment 0.498434 new treatment 0.547603 external radiation therapy 0.527756 brain 0.588207 PDQ summary 0.519792 effects tumor treatment 0.543564 Intracavitary radiation therapy 0.548993 radiation treatment 0.484529 cancer clinical trials 0.558097 tumor 0.711831 treatment options 0.489122 internal radiation therapy 0.557881 cancer 0.593059 standard treatment 0.499934 spinal cord tumors 0.49494	CLICK HERE
1748	National Cancer Institute	Html	en	Formaldehyde and Cancer Risk	A fact sheet that discusses formaldehyde and its possible association with cancer. Includes resources for more information.	U.S. Consumer Product 0.507182 potential health effects 0.45175 nasopharyngeal cancer 0.446819 formaldehyde resins 0.646729 paper product coatings 0.444118 formaldehyde exposure 0.974129 cumulative exposure 0.471192 case-control studies 0.464784 health care professionals 0.44942 laboratory studies 0.445025 building materials 0.458544 highest estimated formaldehyde 0.647871 formaldehyde exposure limit 0.684002 long-term health effects 0.450096 probable human carcinogen 0.44463 formaldehyde exposure levels 0.675206 industrial workers 0.445134 short-term health effects 0.476808 Environmental Protection Agency 0.476151 workplace exposure 0.472844 myeloid leukemia 0.515754 high formaldehyde levels 0.685556 pressed-wood products 0.507453 occupational formaldehyde exposure 0.700409	Product Safety Commission 0.506904 cohort study 0.490021 National Toxicology Program 0.502466 household products 0.463834 British industry workers 0.444394 U.S. Environmental Protection 0.477699 occupational exposure 0.487391 Occupational Safety 0.475151 Emergency Management Agency 0.463126 human carcinogen 0.45778 National Cancer Institute 0.452741 lymphatic systems 0.444691 formaldehyde gas 0.693298 Health Administration 0.456674 NCI cohort 0.451429 NCI case-control study 0.460446 occupational exposure limits 0.480797 Consumer Product Safety 0.50691 NCI industrial cohort 0.459283 lung cancer deaths 0.469841 funeral industry workers 0.472946 lung cancer mortality 0.44468 formaldehyde content 0.617511 prolonged exposure 0.474993	CLICK HERE
1756	National Cancer Institute	Html	en	Alcohol and Cancer Risk	A fact sheet that summarizes the evidence linking alcohol consumption to the risk of various cancers. Includes information about factors that affect the risk of alcohol-associated cancers.	major risk factor 0.235988 esophageal cancer 0.270931 alcohol content 0.304765 alcohol-associated cancer risk 0.218724 alcohol dehydrogenase 0.277499 Heavy alcohol 0.291007 alcohol consumption 0.743494 modestly increased risk 0.222903 colorectal cancer risk 0.261495 alcohol drinkers 0.284781 drinking alcohol 0.321106 alcohol intake 0.325944 ethyl alcohol 0.305684 percent alcohol 0.349039 moderate alcohol drinking 0.333262 Alcohol Abuse 0.303318 studies 0.234236 cancer risk declines 0.219417 alcohol 0.928418 pure alcohol 0.321046	Moderate alcohol intake 0.283695 esophageal squamous cell 0.212278 breast cancer risk 0.237174 S. Alcohol drinking 0.301428 alcohol-related esophageal cancer 0.211228 breast cancer 0.381145 alcohol drinking 0.503002 neck cancers 0.250896 pancreatic cancer risk 0.215956 neck cancer 0.200912 regular alcohol consumption 0.359735 et al 0.397799 cancer risk 0.361737 cancers 0.264383 oral cavity 0.23106 cancer 0.549181 risk 0.431925 liver cancer 0.219113 enzyme drink alcohol 0.313977	CLICK HERE
16258	National Cancer Institute	Html	es	Exámenes de detección y detección temprana	El NCI apoya y dirige investigación sobre exámenes de detección y detección temprana de cáncer, incluyendo estudios para formular y validar marcadores biológicos.	Estados Unidos.  0.305194 cabo extensión 0.305776 Investigación Oncológica 0.305832 Mejor cuantificación 0.307132 amplia variedad 0.306584 Estados Unidos 0.358649 causarán síntomas 0.306983 cáncer colorrectal 0.434511 cabo análisis 0.306294 memorable estudio nacional 0.309583	sobretratamiento—el diagnóstico 0.307579 socioeconómicos específicos—que 0.307995 gente—con frecuencia 0.307545 cabo el NCI 0.307119 Mejor detección 0.335532 factores genéticos causantes 0.312309 El Programa Nacional Comunitario 0.309532 Nuevas tecnologías 0.306404 detección temprana 0.979153	CLICK HERE
16473	National Cancer Institute	Html	en	Nivolumab Improves Survival for Patients with Recurrent Head and Neck Cancer	A summary of clinical trial results showing that nivolumab (Opdivo®) improved overall survival compared with standard chemotherapy in patients with head and neck squamous cell carcinoma.	platinum-based chemotherapy 0.436007 immune checkpoint inhibitor 0.707571 pembrolizumab block 0.240544 checkpoint inhibitor nivolumab 0.489462 standard therapy group 0.856853 HNSCC tumor growth 0.401684 squamous cells 0.272124 Cancer Therapy Evaluation 0.372634 overall survival 0.94063 broader group 0.255871 poor prognoses 0.250488 median progression-free survival 0.452131 Pittsburgh Medical Center 0.399432 Maura L. Gillison 0.401307 Bristol-Myers Squibb 0.274378 median overall survival 0.493854 patients 0.514717 metastatic HNSCC 0.274208 HNSCC 0.412159 effective second-line therapy 0.394916 Shakun Malik 0.250672 Drug Administration 0.252661 cancer cells 0.262643 treatment-related adverse events 0.35048	Human papillomavirus 0.256631 better treatment 0.263098 unacceptable side effects 0.245803 median follow-up 0.28334 PD-L1—a molecule 0.240638 nivolumab group 0.622355 tumor cells 0.248287 new trial 0.243059 standard chemotherapy 0.417786 Ohio State University 0.396086 median length 0.283635 immune cells 0.271394 salivary glands 0.258435 nasal passages 0.247938 Robert L. Ferris 0.397098 Cancer Institute 0.278018 neck cancer 0.259993 tumor response 0.240293 common adverse events 0.34039 New England Journal 0.393835 oral cavity 0.246829 checkpoint molecule PD-1 0.389662 Earlier studies 0.247274 phase III trial 0.261728	CLICK HERE
16718	National Cancer Institute	Html	es	Estudios clínicos de cáncer en el Centro Clínico de los Institutos Nacionales de la Salud	Información acerca de los estudios clínicos de cáncer en el Centro Clínico de NIH en Bethesda, Maryland.	Centro Clínico 0.997868 investigación clínica 0.340866	Estados Unidos 0.385246 Institutos Nacionales 0.316065	CLICK HERE